Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia


Por: Casado, JA, Valeri, A, Sanchez-Dominguez, R, Vela, P, Lopez, A, Navarro, S, Alberquilla, O, Hanenberg, H, Pujol, R, Segovia, JC, Minguillon, J, Surralles, J, de Heredia, CD, Sevilla, J, Rio, P, Bueren, JA

Publicada: 1 ago 2022
Resumen:
Fanconi anemia (FA) is the most prevalent inherited bone marrow failure (BMF) syndrome. Nevertheless, the pathophysiological mechanisms of BMF in FA have not been fully elucidated. Since FA cells are defective in DNA repair, we hypothesized that FA hematopoietic stem and progenitor cells (HSPCs) might express DNA damage-associated stress molecules such as natural killer group 2 member D ligands (NKG2D-Ls). These ligands could then interact with the activating NKG2D receptor expressed in cytotoxic NK or CD8(+) T cells, which may result in progressive HSPC depletion. Our results indeed demonstrated upregulated levels of NKG2D-Ls in cultured FA fibroblasts and T cells, and these levels were further exacerbated by mitomycin C or formaldehyde. Notably, a high proportion of BM CD34(+) HSPCs from patients with FA also expressed increased levels of NKG2D-Ls, which correlated inversely with the percentage of CD34(+) cells in BM. Remarkably, the reduced clonogenic potential characteristic of FA HSPCs was improved by blocking NKG2D-NKG2D-L interactions. Moreover, the in vivo blockage of these interactions in a BMF FA mouse model ameliorated the anemia in these animals. Our study demonstrates the involvement of NKG2D-NKG2D-L interactions in FA HSPC functionality, suggesting an unexpected role of the immune system in the progressive BMF that is characteristic of FA.

Filiaciones:
Casado, JA:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Valeri, A:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Sanchez-Dominguez, R:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Vela, P:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Lopez, A:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Navarro, S:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Alberquilla, O:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Hanenberg, H:
 Univ Duisburg Essen, Dept Pediat 3, Univ Childrens Hosp Essen, Essen, Germany

 Heinrich Heine Univ, Dept Otorhinolaryngol & Head & Neck Surg, Dusseldorf, Germany

Pujol, R:
 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

 Univ Autonoma Barcelona, IIB St Pau, Hosp La Santa Reu & St Pau, Barcelona, Spain

Segovia, JC:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Minguillon, J:
 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

 Univ Autonoma Barcelona, IIB St Pau, Hosp La Santa Reu & St Pau, Barcelona, Spain

Surralles, J:
 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

 Univ Autonoma Barcelona, IIB St Pau, Hosp La Santa Reu & St Pau, Barcelona, Spain

de Heredia, CD:
 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

 Hosp Univ Vall dHebron, Serv Oncol & Hematol Pediat, Barcelona, Spain

Sevilla, J:
 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

 Hosp Nino Jesus, Stem Cell Transplant Unit, Madrid, Spain

Rio, P:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain

Bueren, JA:
 IIS Fdn Jimenez Diaz, Div Innovat Therapies, CIEMAT, Madrid, Spain

 IIS Fdn Jimenez Diaz, Adv Therapies Unit, Madrid, Spain

 Univ Autonoma Madrid, Madrid, Spain

 Biomed Ctr Res Rare Dis CIBERER, Madrid, Spain
ISSN: 00219738
Editorial
AMER SOC CLINICAL INVESTIGATION INC, 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 132 Número: 15
Páginas:
WOS Id: 000842455700003
ID de PubMed: 35671096
imagen gold, Green Published, All Open Access, Gold, Green

MÉTRICAS